CLAIM CARD
A notable tension emerges between the positive renal protection signal from a surgical context (Kilic 2026) and the broader pattern of null or mixed findings for ACE inhibitors in other aging-related domains across the corpus. The pragmatic finding of high treatment discontinuation (Senanayake 2026) stands in disagreement with any assumption of straightforward long-term geroprotective use. Collectively, these systemic and safety outcomes reinforce that the risk-benefit profile of ACE inhibitors in older adults is complex, with specific benefits in certain procedural contexts coexisting with practical adherence barriers and potential adverse effects.
Evidence grade: exploratory
Contradiction status: none
Publication: 9ab2e887-2e5b-429a-8d89-fd6d7813a028
Provenance: Derivation Web chain
Citation Support
source_1Lin 2026source_2Din 2026source_3Spiegeleer 2025source_4Shen 2025source_5Bene 2025